Dual Antithrombotic Therapy with Dabigatran and Ticagrelor in Patients with Acute Coronary Syndrome and Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention (ADONIS-PCI)

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515056-20-00

Acronym

NBK182/1/2020

Enrollment

2230

Registered

2024-11-24

Start date

2021-07-31

Completion date

2025-10-31

Last updated

2025-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome and Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

Brief summary

First major or clinically relevant non-major bleeding event (ISTH)

Detailed description

Composite of thromboembolic events (MI, stroke, systemic embolism) or death or unplanned revascularization (PCI or CABG)

Interventions

DRUGBrilique 60 mg film-coated tablets

DRUGBrilique 90 mg film-coated tablets

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
First major or clinically relevant non-major bleeding event (ISTH)	—

Secondary

Measure	Time frame
Composite of thromboembolic events (MI, stroke, systemic embolism) or death or unplanned revascularization (PCI or CABG)	—

Countries

Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026